Financial Performance - The company's operating revenue for 2024 was CNY 740.32 million, a decrease of 5.92% compared to CNY 786.87 million in 2023[25]. - The net profit attributable to shareholders for 2024 was CNY 14.41 million, down 67.11% from CNY 43.81 million in 2023[25]. - The cash flow from operating activities for 2024 decreased by 66.96% to CNY 32.19 million, compared to CNY 97.42 million in 2023[25]. - Basic earnings per share for 2024 were CNY 0.11, a decline of 66.67% from CNY 0.33 in 2023[26]. - The company's total assets at the end of 2024 were CNY 1.20 billion, down 8.93% from CNY 1.32 billion at the end of 2023[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -1.97 million in 2024, a decline of 107.95% from CNY 24.85 million in 2023[25]. - The company's gross profit margin decreased by 2.09 percentage points to 45.60% compared to the previous year[102]. - The company reported a significant decline in sales volume for industrial detection instruments, down 25.87% year-on-year, influenced by reduced demand in the new energy market[104]. - The online monitoring instruments saw a sales volume decrease of 22.08% year-on-year, attributed to intense market competition[104]. Research and Development - Research and development expenses accounted for 19.82% of operating revenue in 2024, a decrease of 1.33 percentage points from 21.15% in 2023[26]. - The total R&D investment for the year was approximately ¥146.77 million, a decrease of 11.81% compared to the previous year[74]. - The company continues to maintain a high level of R&D investment, impacting short-term profits but aimed at long-term growth[28]. - The company has established a first-class R&D team with expertise across various fields, enhancing R&D efficiency and innovation capabilities[87]. - The company has developed core technologies including ultra-low emission online monitoring technology and volatile organic compounds (VOCs) analysis technology, which are at the product stage and are domestically leading[67]. - The company has developed advanced technologies such as high-reliability sealing and decomposition devices, and various detection technologies, all of which are at the product stage[68]. - The company has made significant advancements in software technologies, including cloud-native applications and deep learning intelligent analysis technologies, all leading domestically[68]. - The company is focusing on continuous R&D investment and innovation to meet the high standards required for precision instruments, which have significant technical barriers to entry[55]. Market Strategy and Expansion - The company is focusing on expanding its market presence in 23 countries, including Ecuador, Peru, and Mexico, to enhance its international competitiveness[42]. - The company is actively participating in the Guangdong Alliance bulk procurement for ultrasonic knives, aiming to strengthen its market position in the medical device sector[41]. - The company is focusing on expanding its market presence in the semiconductor and new energy sectors, with significant growth potential anticipated in the coming years[79]. - The company is committed to becoming a competitive player in the precision scientific instruments and life health sectors, with a vision of being a respected Chinese enterprise[132]. - The company is strategically positioned for future growth through its investment in new technologies and market expansion efforts[152]. Corporate Governance - The company has established a comprehensive governance structure in compliance with relevant laws and regulations, ensuring effective operation and accountability[140]. - The independent directors actively participated in decision-making, enhancing the board's professionalism and efficiency[141]. - The company has no significant issues regarding independence from its controlling shareholders, maintaining a clear separation in operations and finances[143]. - The company’s governance practices align with the standards set by the China Securities Regulatory Commission and the Shanghai Stock Exchange[143]. - The company held 6 board meetings during the year, with 5 conducted via communication methods and 1 combining on-site and communication methods[162]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of 1.00 CNY per 10 shares for the 2024 fiscal year, amounting to approximately 12,532,241.10 CNY, which accounts for 86.99% of the projected net profit attributable to shareholders[180][183]. - The cumulative cash dividend over the last three fiscal years amounts to 65,118,805.90 CNY, with an average net profit of 35,342,918.44 CNY, resulting in a cash dividend ratio of 184.25%[185]. - The company has maintained a robust communication process with minority shareholders regarding profit distribution proposals[181]. - The company ensures that independent directors fulfill their responsibilities and that minority shareholders have opportunities to express their opinions on profit distribution[181]. Financial Position and Investments - The company reported a significant improvement in operational efficiency, contributing to a 46.18% increase in the financial director's shareholding[150]. - The company's cash and cash equivalents increased by 73.45% to 88.28 million yuan, primarily due to the recovery of financial products[115]. - The company's investment activities generated a net cash flow of 77.64 million yuan, a significant increase compared to the previous year's negative cash flow[113]. - The company has a strong after-sales service team, enhancing market competitiveness and customer satisfaction[86]. - The company is exposed to financial risks if government support for its industry decreases, potentially affecting its operating performance[92]. Talent Development and Employee Engagement - The company is committed to talent development, optimizing its workforce structure and enhancing its training systems to attract and retain talent[46]. - The company has established a competitive salary system based on performance evaluation, ensuring key talents are compensated favorably in the market[171]. - A training plan for 2024 is in place, focusing on new hires and existing employees, with specialized training for key positions to ensure competency[172]. - The overall employee engagement in stock ownership has risen, with a notable 34.22% increase for Wei Binsong, indicating a positive shift in company culture[150]. Risk Management - The company has detailed various risks and countermeasures in the report, which can be found in the "Risk Factors" section[4]. - The company faces risks related to market demand fluctuations due to macroeconomic conditions, which may impact future revenue growth[91]. - The company is focusing on maintaining a high proportion of R&D investment, which has led to a negative taxable income in recent years[97].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 134,286,929.36, representing a 16.87% increase compared to CNY 114,906,354.26 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 5,450,922.09, an improvement from a loss of CNY 33,616,386.19 in the previous year[4] - The basic and diluted earnings per share were both negative CNY 0.04, an improvement from negative CNY 0.25 in the same period last year[4] - Net profit for Q1 2025 was -¥5.45 million, an improvement from -¥33.62 million in Q1 2024, indicating a significant reduction in losses[20] Cash Flow - The net cash flow from operating activities was a negative CNY 24,458,924.76, worsening from a negative CNY 14,945,672.69 year-on-year[4] - Cash flow from operating activities showed a net outflow of -¥24.46 million in Q1 2025, compared to -¥14.95 million in Q1 2024[24] - Cash inflow from investment activities was ¥115.89 million in Q1 2025, a decrease from ¥206.91 million in Q1 2024[24] - Cash outflow from investment activities totaled ¥133.05 million in Q1 2025, down from ¥149.18 million in Q1 2024[24] - The net increase in cash and cash equivalents was -$28,976,358.19, a significant decline from an increase of $54,317,165.21 in the prior period[25] - The ending balance of cash and cash equivalents was $56,241,866.39, down from $104,036,896.49, representing a decrease of approximately 46.0%[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,179,462,076.18, a decrease of 1.86% from CNY 1,201,819,195.09 at the end of the previous year[5] - The equity attributable to shareholders decreased by 6.68% to CNY 739,360,356.23 from CNY 792,297,427.81[5] - Total liabilities increased to ¥440.10 million in the latest reporting period from ¥409.52 million previously, indicating a rise in financial obligations[17] - Current liabilities decreased to RMB 353,429,580.57 from RMB 376,336,646.15, showing a reduction of approximately 6.06%[16] Research and Development - Research and development expenses totaled CNY 35,440,733.04, down 19.06% from CNY 43,785,860.20, with R&D expenses accounting for 26.39% of operating revenue, a decrease of 11.72 percentage points[5] - Research and development expenses for Q1 2025 were ¥35.44 million, down 19% from ¥43.79 million in Q1 2024[20] Operational Strategy - The company plans to continue focusing on improving operational efficiency and reducing costs to enhance profitability in future quarters[7] Shareholder and Financing Activities - The company has no significant changes in the shareholder structure or related party transactions during the reporting period[12] - The company raised ¥60 million through borrowings in Q1 2025, compared to ¥40 million in Q1 2024, reflecting increased financing activities[24] - Cash flow from financing activities totaled $48,362,784.97, an increase from $28,466,172.98 in the previous period, reflecting a growth of approximately 70.0%[25]

证券代码：688600 证券简称：皖仪科技 公告编号：2025-024 安徽皖仪科技股份有限公司（以下简称"公司"）第五届监事会第十六次会 议于 2025 年 4 月 24 日以通讯方式召开，会议通知已于 2025 年 4 月 22 日以电话、 短信及口头等方式送达公司全体监事。根据《公司章程》《监事会会议事规则》 相关规定，全体监事一致同意豁免本次监事会会议提前 5 日的通知期限。本次会 议由监事会主席王国东先生主持，会议应出席监事 3 人，实际出席监事 3 人。本 次会议的召集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）等法律、法规和《安徽 皖仪科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、监事会会议审议情况 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽皖仪科技股份有限公司 第五届监事会第十六次会议决议公告 一、监事会会议召开情况 综上，监事会认为公司和激励对象均未发生不得授予限制性股票的情形，本 次激励计划规定的授予条 ...

证券代码：688600 证券简称：皖仪科技 公告编号：2025-023 安徽皖仪科技股份有限公司 第五届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 安徽皖仪科技股份有限公司（以下简称"公司"）第五届董事会第二十一次会议 于 2025 年 4 月 24 日以通讯方式召开，会议通知已于 2025 年 4 月 22 日以电话、短 信及书面等方式送达公司全体董事。根据《公司章程》《董事会议事规则》相关规定， 全体董事一致同意豁免本次董事会会议提前 5 日的通知期限。会议由董事长臧牧先 生主持。本次会议应出席董事 6 人，实际出席董事 6 人。本次会议的召集、召开符 合《中华人民共和国公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于向 2025 年限制性股票激励计划激励对象首次授予限制性股 票的议案》 根据《上市公司股权激励管理办法》、公司《激励计划（草案）》及其摘要的相 关规定和公司 2025 年第二次临时股东大会的授权，董事会认为 ...

安徽皖仪科技股份有限公司 一、首次授予限制性股票激励计划的分配情况 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票 均未超过股权激励计划提交股东大会审议时公司总股本的 1%。公司全部有效期内的激励计 划所涉及的标的股票总数累计不超过股权激励计划提交股东大会审议时公司股本总额的 20%。 2、以上激励对象中公司副总经理臧辉先生为公司控股股东、实际控制人臧牧先生之弟。 3、本激励计划首次授予的激励对象不包括独立董事、监事、单独或合计持有公司 5% 以上股份的股东、上市公司实际控制人及其配偶、父母、子女及外籍员工。 4、上表中数值若出现总数与各分项数值之和尾数不符，系因四舍五入所致。 2025 年限制性股票激励计划首次授予激励对象名单 （首次授予日） | 序号 | 姓名 | 国籍 | 职务 | 获授的限制 | 占授予限制性 | 占本激励计划 公告日公司股 | | --- | --- | --- | --- | --- | --- | --- | | | | | | 性股票数量 | 股票总数的比 | | | | | | | （万股） | 例 | 本总额的比例 | | | | 一、董事、高 ...

安徽皖仪科技股份有限公司（以下简称"公司"）监事会根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上 海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》《科创板上市公司自律监管指 南第 4 号——股权激励信息披露》等相关法律法规及规范性文件和《公司章程》 的有关规定，对公司 2025 年限制性股票激励计划（以下简称"本次激励计划"） 首次授予激励对象名单（首次授予日）进行了核查，现发表核查意见如下： 一、本次激励计划首次授予激励对象均不存在《上市公司股权激励管理办 法》规定的不得成为激励对象的情形： 1、最近 12 个月内被证券交易所认定为不适当人选； 2、最近 12 个月内被中国证监会及其派出机构认定为不适当人选； 安徽皖仪科技股份有限公司监事会 关于公司 2025 年限制性股票激励计划首次授予 激励对象名单的核查意见（首次授予日） 5、法律法规规定不得参与上市公司股权激励的； 6、中国证监会认定的其他情形。 二 ...

重要内容提示： 安徽皖仪科技股份有限公司（以下简称"公司"）《2025 年限制性股票激励计划（草 案）》（以下简称《" 激励计划（草案）》"或"本激励计划"）规定的限制性股票授予条件 已经成就，根据公司 2025 年第二次临时股东大会的授权，公司于 2025 年 4 月 24 日 分别召开第五届董事会第二十一次会议和第五届监事会第十六次会议，审议通过了 《关于向 2025 年限制性股票激励计划激励对象首次授予限制性股票的议案》，确定 2025 年 4 月 24 日为首次授予日，以 16.17 元/股的授予价格向 150 名激励对象授予 一、限制性股票授予情况 （一）本次限制性股票激励计划已履行的决策程序和信息披露情况 1、2025 年 4 月 7 日，公司召开第五届董事会第二十次会议、第五届监事会第十 五次会议，会议审议通过了《关于公司<2025 年限制性股票激励计划（草案）>及其 摘要的议案》等议案。监事会对本激励计划的相关事项进行了核查并出具了相关核 查意见。 证券代码：688600 证券简称：皖仪科技 公告编号：2025-025 安徽皖仪科技股份有限公司 关于向 2025 年限制性股票激励计划激励对象首 ...

证券简称：皖仪科技 证券代码：688600 上海荣正企业咨询服务（集团）股份有限公司 关于 安徽皖仪科技股份有限公司 2025 年限制性股票激励计划 首次授予相关事项 之 独立财务顾问报告 2025 年 4 月 | 一、释义 | 3 | | --- | --- | | 二、声明 | 4 | | 三、基本假设 | 5 | | 四、独立财务顾问意见 | 6 | | （一）本次限制性股票激励计划的审批程序 6 | | | （二）本次限制性股票授予条件说明 7 | | | （三）本次限制性股票的首次授予情况 7 | | | （四）实施本次激励计划对相关年度财务状况和经营成果影响的说明 10 | | | （五）结论性意见 10 | | | 五、备查文件及咨询方式 | 11 | | （一）备查文件 11 | | | （二）咨询方式 11 | | 一、释义 以下词语如无特殊说明，在本文中具有如下含义： | 本公司、公司、上市 | 指 | 安徽皖仪科技股份有限公司（含下属分公司、控股子公司） | | --- | --- | --- | | 公司 | | | | 本激励计划、本计划 | 指 | 安徽皖仪科技股份有限公司 202 ...

法律意见书 安徽天禾律师事务所 关于安徽皖仪科技股份有限公司 2025 年限制性股票激励计划首次授予事项 之 法律意见书 安徽天禾律师事务所 ANHUI TIANHE LAW OFFICE 地址：合肥市濉溪路 278 号财富广场 B 座东楼 16 层 电话：（0551）62642792 传真：（0551）62620450 1 法律意见书 安徽天禾律师事务所 关于安徽皖仪科技股份有限公司 2025 年限制性股票激励计划首次授予事项 之法律意见书 天律意 2025 第 00959 号 致：安徽皖仪科技股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、中国证券监督管理委员会（以下简称"证监 会"）《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易 所科创板股票上市规则》（以下简称"《上市规则》"）及《科创板上市公司信息披 露业务指南第 4 号——股权激励信息披露》（以下简称"《披露指南》"）等法 律、行政法规、部门规章及规范性文件（以下统称"法律法规"）和《安徽皖仪 科技股份有限公司章程》（以下简称"《公司章程》"）、《安 ...

证券代码：688600 证券简称：皖仪科技 公告编号：2025-020 安徽皖仪科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 23 日 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 39 | | --- | --- | | 普通股股东人数 | 39 | | 2、出席会议的股东所持有的表决权数量 | 12,159,749 | | 普通股股东所持有表决权数量 | 12,159,749 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 17.0856 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 17.0856 | 注：上述出席会议的股东所持有表决权数量占公司表决权数量的比例，已剔除公司已回购的 股份。 ...